Please provide your email address to receive an email when new articles are posted on . Asundexian did not prevent stroke or systemic embolism vs. apixaban in patients with atrial fibrillation despite ...

A recent review identifies Embolic Stroke of Undetermined Source (ESUS) as accounting for one out of every six ischemic ...

Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US and Europe later this year.

Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...

Emboline has secured $20 million for its embolic protection system, designed to minimize stroke risk associated with transcatheter aortic valve replacement procedures. The Santa Cruz, CA-based company ...

A series of neutral trials on anticoagulation in embolic stroke of undetermined source (ESUS) has moved the needle scientifically but left physicians with questions about secondary prevention and the ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

The Appraisal Committee considered evidence submitted by Daiichi Sankyo and a review of this submission by the Evidence Review Group (ERG). The primary source of evidence was ENGAGE AF‑TIMI 48, a ...

Patients with embolic stroke of undetermined source (ESUS) who are found to have signs of left ventricular dysfunction may benefit from anticoagulation to prevent a further stroke, a new exploratory ...

Patients with pulmonary adenocarcinoma consulted the neurology department due to multiple initial symptoms of cerebral ischaemia. Examination of each patient revealed pulmonary embolism, the ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...